We are live on
!
Find out more
ACM
ACT Capital Management Portfolio holdings
AUM
$153M
This Fund
S&P 500
This Quarter
Est. Return
+34.85%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$124M
AUM Growth
–
Cap. Flow
+$115M
Cap. Flow
% of AUM
93.08%
Top 10 Holdings %
Top 10 Hldgs %
67.23%
Holding
58
New
58
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Krystal Biotech
KRYS
|
+$12.7M |
| 2 |
Chevron
CVX
|
+$12M |
| 3 |
ExxonMobil
XOM
|
+$9.57M |
| 4 |
TG Therapeutics
TGTX
|
+$8.78M |
| 5 |
Viking Therapeutics
VKTX
|
+$7.3M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 60.01% |
| 2 | Energy | 21.39% |
| 3 | Consumer Discretionary | 4.59% |
| 4 | Technology | 2.59% |
| 5 | Financials | 1.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Devon Energy
DVN
$50.9B
| $806K | 0.65% |
+22,000
| New | +$768K |
|
27
UiPath
PATH
$6.41B
| $770K | 0.62% |
+47,000
| New | +$731K |
|
28
Kura Oncology
KURA
$826M
| $768K | 0.62% |
+73,900
| New | +$775K |
|
29
Teva Pharmaceuticals
TEVA
$41.2B
| $718K | 0.58% |
+23,000
| New | +$567K |
|
30
Replimune Group
REPL
| $598K | 0.48% |
+61,500
| New | +$523K |
|
31
Scholar Rock
SRRK
$5.87B
| $529K | 0.43% |
+12,000
| New | +$450K |
|
32
Apogee Therapeutics
APGE
$10.2B
| $528K | 0.43% |
+7,000
| New | +$441K |
|
33
Crescent Energy
CRGY
$3.69B
| $514K | 0.42% |
+61,312
| New | +$538K |
|
34
GeneDx Holdings
WGS
$2.05B
| $390K | 0.32% |
+3,000
| New | +$412K |
|
35
Palisade Bio
PALI
$341M
| $353K | 0.29% |
+150,000
| New | +$288K |
|
|
ACOG
36
Alpha Cognition
ACOG
$190M
| $335K | 0.27% |
+51,500
| New | +$325K |
|
37
Liquidia Corp
LQDA
$7.72B
| $293K | 0.24% |
+8,500
| New | +$242K |
|
38
Kyverna Therapeutics
KYTX
$455M
| $236K | 0.19% |
+25,100
| New | +$186K |
|
39
Babcock & Wilcox
BW
$1.41B
| $231K | 0.19% |
+36,500
| New | +$180K |
|
40
Aldeyra Therapeutics
ALDX
$96.5M
| $212K | 0.17% |
+41,000
| New | +$211K |
|
|
NKLR
41
Terra Innovatum Global N.V.
NKLR
$578M
| $208K | 0.17% |
+45,000
| New | +$316K |
|
42
Praxis Precision Medicines
PRAX
$8.58B
| $206K | 0.17% |
+700
| New | +$130K |
|
|
ESPR
43
DELISTED
Esperion Therapeutics
ESPR
| $176K | 0.14% |
+47,500
| New | +$153K |
|
44
Lightspeed Commerce
LSPD
$1.25B
| $151K | 0.12% |
+12,500
| New | +$148K |
|
|
DAWN
45
DELISTED
Day One Biopharmaceuticals
DAWN
| $120K | 0.1% |
+12,900
| New | +$108K |
|
46
Travere Therapeutics
TVTX
$5.33B
| $115K | 0.09% |
+3,000
| New | +$97.5K |
|
47
Amylyx Pharmaceuticals
AMLX
$2.31B
| $109K | 0.09% |
+9,000
| New | +$122K |
|
48
Weyerhaeuser
WY
$16.9B
| $107K | 0.09% |
+4,500
| New | +$104K |
|
49
Stratasys
SSYS
$697M
| $86.8K | 0.07% |
+10,000
| New | +$99.1K |
|
50
Biohaven
BHVN
$2.08B
| $84.7K | 0.07% |
+7,500
| New | +$92.9K |
|
Similar funds
BCI
APW
IFA
BGAI
DAM
BVC
RHAM
EG
ACT Capital Management's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for ACT Capital Management, which disclosed 58 positions worth $124M. Its ten largest holdings account for 67% of the portfolio.
Its largest position is Krystal Biotech: 60,500 shares worth $14.9M.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, followed by Energy and Consumer Discretionary.
- ACT Capital Management's largest Q4 2025 buy was Krystal Biotech: 60,500 shares worth $14.9M.
- ACT Capital Management's ten largest holdings make up 67% of its $124M portfolio in Q4 2025.
- ACT Capital Management disclosed 58 positions in Q4 2025, its first 13F filing on record.
Based on ACT Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.